Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Abbott Laboratories' HUMIRA (Adalimumab) Approved in Europe for Severe Active Pediatric Crohn's Disease


Tuesday, 27 Nov 2012 02:00am EST 

Abbott Laboratories announced that the European Commission has approved HUMIRA (adalimumab) for the treatment of pediatric patients aged 6 to 17 years with severe active Crohn's disease (CD) who failed, are intolerant to, or have contraindications to conventional therapy. With this approval, HUMIRA becomes the first biologic treatment approved for these patients in more than five years. Pediatric CD is a chronic, debilitating condition of the gastrointestinal (GI) tract that affects up to 200,000 children worldwide. CD, which is a type of inflammatory bowel disease, most commonly involves the end of the small intestine and the beginning of the large intestine. In addition to symptoms such as abdominal pain, weight loss and diarrhea, pediatric CD can affect children in several ways unique to this age group, including delayed growth and/or puberty. 

Company Quote

42.11
-0.21 -0.50%
22 Aug 2014